Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

MarketScan® secukinumab cohort: Inclusion criteria: * Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim) * Included patients age ≥18 years as of the year of index date * Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period * Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period * Included patients with continuous medical/pharmacy coverage in the 1-year post-index period Exclusion criteria: * Excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date * Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date) * Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort) BADBIR cohort: Inclusion criteria: * Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020 * Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date * Index date will be the date of the first secukinumab treatment date * Included patients with age ≥ 18 on the index date * Included patients with psoriasis diagnosis in the pre-index period and index date * Included patients with ≥ 1 year follow-up period * Follow-up period is the gap between patient's last visit date and index date Exclusion criteria: * Excluded patients with psoriatic arthritis (PsA) prior to and on index date * Excluded patients with any biologics/apremilast including secukinumab in the baseline period